Budesonide/formoterol in the treatment of asthma

References

• National Institutes of Health: National Heart Lung and Blood Institute, National Asthma Education and Prevention Programme. Expert panel report III: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD, USA (2007).
   Google Scholar
• Kuna P, Kuprys I. Symbicort turbuhaler: a new concept in asthma management. Int. J. Clin. Pract.56(10), 797–803 (2002).
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Bronchial asthma. WHO fact sheet 206, Geneva, Switzerland (2000).
   Google Scholar
• Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J. Allergy Clin. Immunol.106, 493–499 (2000).
   PubMed Web of Science ®Google Scholar
• National Institutes of Health: National Heart, Lung, and Blood Institute Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institutes of Health: National Heart, Lung, and Blood Institute, Bethesda, MD, USA (2007) (Update).
   Google Scholar
• British Thoracic Society. British guidelines on the management of asthma. Thorax58(Suppl. 1), 1–94 (2003).
   PubMedGoogle Scholar
• Symbicort (budesonide/formoterol) prescribing information. Astrazeneca, L.P. In: Physician’s Desk Reference. (62nd Edition). Thomas Healthcare Inc., NJ, USA 642–649 (2007).
   Google Scholar
• Djukanovic R, Wilson JW, Britten FM et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis.145, 669–674 (1992).
   PubMed Web of Science ®Google Scholar
• Bergstrand H, Lundquist B, Petersson BA. The glucocorticoid budesonide, partially blocks histamine release from human lung tissue in vitro. Allergy41, 319–326 (1986).
   PubMed Web of Science ®Google Scholar
• Laitinen LA, Laitinen A, Haahitela T. A comparative study of the effects of an inhaled corticosteroid, budesonide and a β2 agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized double blind parallel group controlled trial. J. Allergy Clin. Immunol.90, 32–42 (1992).
   PubMed Web of Science ®Google Scholar
• Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J. Allergy Clin. Immunol.104, S175–S183 (1999)
   PubMed Web of Science ®Google Scholar
• Pulmicort turbuhaler (budesonide inhalation powder) prescribing information. Astra Pharmaceuticals, L.P. In: Physician’s Desk Reference. (53rd Edition). Medical Economics Company, NJ, USA 587–589 (1999).
   Google Scholar
• Thalen A, Brattsand, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm. Venereol.69(Suppl.), 11–19 (1989).
   Google Scholar
• Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E. Influence of 16 α, 17 α acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J. Steroid Biochem.16, 779–786 (1982).
   PubMedGoogle Scholar
• Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E. Development of new corticosteroids with a very high ratio between topical and systemic activities. Eur. J. Respir. Dis.63(Suppl.), 62–73 (1982).
   PubMedGoogle Scholar
• Barnes PJ. Effect of β-agonists on inflammatory cells. J. Allergy Clin. Immunol.104, S10–S17 (1999).
   PubMed Web of Science ®Google Scholar
• Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir. Med.92, 1017–1021 (1998).
   PubMed Web of Science ®Google Scholar
• Seberova E, Anderson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir. Med.94, 607–611 (2000).
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med.160, 244–249 (1999).
   PubMed Web of Science ®Google Scholar
• Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur. Respir. J.17, 1070–1077 (2001).
   PubMed Web of Science ®Google Scholar
• Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax57, 237–241 (2002).
   PubMed Web of Science ®Google Scholar
• Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J.18, 261–268 (2001).
   Google Scholar
• Aggarwal SK, Frith LJ, Ho M et al. Fluticasone propionate/salmeterol delivered from a single inhaler demonstrates synergistic benefits in asthma. Am. J. Respir. Crit. Care Med.167, 890 (2003) (Abstract).
   Google Scholar
• Mak JC, Nishikawa M, Barnes PJ. Glucocorticoids increase β2-adrenergic receptor transcription in human lung. Am. J. Physiol.268(1 Pt 1), L41–L46 (1995).
   PubMed Web of Science ®Google Scholar
• Baraniuk JM, Ali M, Brody D et al. Glucocoriticoids induce β2-adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med.155, 704–710 (1997).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur. Respir. J.19, 182–191 (2002).
   PubMed Web of Science ®Google Scholar
• Jonsson G, Astrom A, Andersson P. Budesonide is ametabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos.23 , 137–142 (1995).
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Postma DA et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med.337, 1405–1411 (1997).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am. J. Respir. Crit. Care Med.164(8 Pt 1), 1392–1397 (2001).
   PubMed Web of Science ®Google Scholar
• Lalloo UG, Malolepszy J, Kozma D et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroids in adults with mild-to-moderate asthma. Chest123, 1480–1487 (2003).
   PubMed Web of Science ®Google Scholar
• Tal A, Simon G, Vermeulen JH, Petru V et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonol.34, 342–350 (2002).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bantje TA, Gomes MJ et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am. J. Respir Med.2, 275–281 (2003).
   PubMedGoogle Scholar
• Buhl R, Creemers JPHM, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir. Med.97, 323–330 (2003).
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Arvisson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol versus salmeterol/fluticasone in single inhalers. Pulm. Pharmacol. Ther.14, 29–34 (2001).
   PubMed Web of Science ®Google Scholar
• Buhl R. Budesonide/formoterol for the treatment of asthma. Expert Opin. Pharmacother.4(8), 1393–1406 (2003).
   PubMed Web of Science ®Google Scholar
• Aalbers R, Backer V, Kava TTK et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed –dose salmeterol/fluticasone in moderate to severe asthma. Curr. Med. Res. Opin.20(2), 225–240 (2004).
   PubMed Web of Science ®Google Scholar
• Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: A randomized trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir. Med.100, 1152–1162 (2006).
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MK, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int. J. Clin. Pract.61(5), 725–736 (2007).
   PubMed Web of Science ®Google Scholar
• Busse WW, Chervinsky P, Condemi J et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J. Allergy Clin. Immunol.101, 457–463 (1998).
   PubMed Web of Science ®Google Scholar
• Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. The Italian Study Group. Chest117, 440–446 (2000).
   PubMed Web of Science ®Google Scholar
• Stallberg B, Olsson P, Jorgensen LA, Lindarck N, Ekstrom T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int. J. Clin. Pract.57(8), 656–661 (2003).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Sears MR, Boulet LP et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can. Respir. J.10(8), 427–434 (2003).
   PubMedGoogle Scholar
• Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir. Med.98, 464–475 (2004).
   PubMed Web of Science ®Google Scholar
• Canonica GW, Castellani P, Cazzola M et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm. Pharmacol. Ther.17, 239–247 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Boulet LP, Follows RMA. The CONCEPT Trial: a 1-year, multicenter, randomized double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin. Therapeut.27(4), 393–406 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Woude HJ, Boorsma M, Bergqvist PBF, Aalbers R. Symbicort produces relief of dyspnea in one minute. Am. J. Respir. Crit. Care Med.165(Suppl.), 567 (2002) (Abstract).
   Google Scholar
• Balang VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther.19, 139–147 (2006).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to moderate asthma: a randomized double blind trial. Chest129(2), 246–256 (2006).
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr.Med. Res. Opin.20(9), 1403–1418 (2004).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bisqarrd H, Godard PP et al. Budesonide/formoterol combination therapy for both maintenance and reliever medication in asthma. Am. J. Resp. Crit. Care Med.171(2), 129–136 (2005).
   PubMed Web of Science ®Google Scholar
• Rabe K, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study. Lancet368(9537), 744–753 (2006).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Boulet LP, Peters, MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs high-dose salmeterol/fluticasone. Respir. Med.101, 2437–2446 (2007).
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J.26, 819–828 (2005).
   PubMed Web of Science ®Google Scholar
• Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered dose inhaler in adults and adolescents with moderate to severe asthma. Drugs66(17), 2235–2254 (2006).
   PubMed Web of Science ®Google Scholar
• Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone nad formoterol alone in adolescents and adults with asthma. Clin. Ther.29(5), 823–843 (2007).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Pedersen S. Measuring efficacy and safety of different inhaled corticosteroid preparations. J. Allergy Clin. Immunol.102, 879–886 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes N. Relative safety and efficacy of inhaled corticosteroids. J. Allergy Clin. Immunol.101, S460–S464 (1998).
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med.343, 1064–1069 (2000).
   PubMed Web of Science ®Google Scholar
• Schreurs AJ, Sinninghe Damste HEJ, de Graaff CS, Greefhorst APM. A dose response study with formoterol turbuhaler as maintenance therapy in asthmatic patients. Eur. Respir. J.9, 1678–1683 (1996).
   PubMed Web of Science ®Google Scholar
• Ekstrom T, Ringdal N, Tukiainen P et al. A 3-month comparison of formoterol with terbutaline via turbuhaler: a placebo-controlled study. Ann. Allergy Asthma Immunol.81, 225–230 (1998).
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Busse WW. Asthma. JAMA278, 1855–1873 (1997).
   PubMed Web of Science ®Google Scholar
• Meyer RJ. Supplemental new drug application for changes to the pregnancy subsection of the precautions section related to a change in the pregnancy category for Pulmicort Turbuhaler ‘C’ to ‘B’. AstraZeneca LP. US FDA, Department of Health and Human Services (2001).
   Google Scholar
• Totterman KJ, Huhti L, Sutinen E et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur. Respir. J.12, 573–579 (1998).
   PubMed Web of Science ®Google Scholar
• Lotvall J, Persson G, Larsson P, Mardell C, Rosenborg J. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice-daily formoterol 12 µg (9 µg delivered). Eur. Respir. J.19(Suppl. 25), 103 (1997).
   Google Scholar
• Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur. J. Clin. Pharmacol.56, 363–370 (2000).
   PubMed Web of Science ®Google Scholar
• Ind P, Borszormenyi Nagy G, Pietinalho A et al. Formoterol 4.5 µg, used as needed via turbuhaler was as safe and well tolerated as terbutaline 0.5 µg. Eur. Respir. J.14(Suppl. 30), S148 (1999).
   Google Scholar
• Tattersfield A, Lofdahl CG, Postma DS et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomized trial. Lancet357, 257–261 (2001).
   PubMed Web of Science ®Google Scholar
• Malolepszy J, Boszormenyi Nagy G, Selroos O, Larsso P, Brander R. Safety of formoterol turbuhaler at cumulatie dose of 90 µg in patients with acute bronchial obstruction. Eur. Respir. J.18, 928–934 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PBF. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int. J. Clin. Pract.56(6), 427–433 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenhall L, Elvstrand A, Tilling B et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir. Med.97, 702–708 (2003).
   PubMed Web of Science ®Google Scholar
• Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm. Pharmacol. Ther.16(3), 147–151 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial. Chest129, 15–26 (2006).
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer, RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest124, 70–74 (2003).
   PubMed Web of Science ®Google Scholar
• Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting β2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst. Rev.4, CD005533 (2005).
   Google Scholar
• Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting β2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst. Rev.4, CD005535 (2005).
   Google Scholar